Patients who had uterine sarcoma, including four patients with ESS and three patients with LMS, were treated for 29.2 months with this medication, demonstrating that aromatase inhibitors are helpful in the treatments of ESS [117]. The gene discussed is CYP19A1; the disease is endometrioid stromal sarcoma.